Technical Analysis for ABBV - AbbVie Inc.
|Grade||Last Price||% Change||$ Change|
ABBV closed down 0.21 percent on Tuesday, January 17, 2017, on approximately normal volume. It was able to find support at its 50 day moving average. It was able to bounce off of its 200 day moving average, an important long-term support line.
Earnings due: 2017-01-27
Trend Table & Recent Alerts
|Weak or Absent||Flat||Up||Down|
|See historical ABBV trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||50 DMA Support||Bullish||0.00%|
|Jan 17||200 DMA Support||Bullish||0.00%|
|Jan 13||Upside 200 DMA Break||Bullish||-0.21%|
|Jan 13||50 DMA Support||Bullish||-0.21%|
|Jan 12||50 DMA Support||Bullish||0.95%|
|Jan 11||Stochastic Sell Signal||Bearish||1.18%|
|Jan 11||Wide Range Bar||Range Expansion||1.18%|
|Jan 11||Downside 200 DMA Break||Bearish||1.18%|
|Jan 11||50 DMA Support||Bullish||1.18%|
|Jan 10||Doji - Bearish?||Reversal||-3.45%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Is ABBV a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ABBV news...
|52 Week High||67.5|
|52 Week Low||50.21|
|200-Day Moving Average||61.7|
|50-Day Moving Average||61.44|
|20-Day Moving Average||62.5|
|10-Day Moving Average||62.78|
|Average True Range||1.18|
|Chandelier Exit (Long, 3 ATRs)||60.96|
|Chandelier Exit (Short, 3 ATRs)||63.96|
|Upper Bollinger Band||64.26|
|Lower Bollinger Band||60.74|
|Percent B (%b)||0.32|